Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Announces Status of Acquisition of Own Shares

share with twitter share with LinkedIn share with facebook
share via e-mail
01/05/2020 | 09:28pm EDT

Press Release

Astellas Announces Status of Acquisition

of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 459,

paragraph 1 of the Companies Act)

TOKYO, January 6, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. "the Company") announced the status of acquisition of its own shares as stated below. The acquisition was implemented pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act.

Particulars

1. Class of shares acquired:

Common stock of the Company

  1. Total number of shares acquired: 7,360,600 shares
  2. Total amount of acquisition cost: 13,738,364,050 yen

4

Period of acquisition:

From December 1, 2019 to December 23, 2019

5

Method of acquisition:

Purchased on the Tokyo Stock Exchange

(Reference)

1. Details of the resolution at the meeting of the Board of Directors (announced on October 31, 2019)

- Class of shares to be acquired:

Common stock of the Company

- Total number of shares to be acquired: Up to 32 million shares

(Ratio to the total number of shares outstanding

[excluding treasury stock]: 1.70%)

- Total amount of acquisition cost:

Up to 50 billion yen

- Period of acquisition:

From November 1, 2019 to January 31, 2020

2. Accumulated Company's own shares acquired through December 31, 2019, pursuant to the above board resolution

- Total number of shares acquired:

20,026,200 shares

- Total amount of acquisition cost:

36,866,306,500 yen

1

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at https://www.astellas.com/en

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively,

  1. the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.
    Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.

Corporate Communications

TEL: +81-3-3244-3201 FAX: +81-3-5201-7473

2

Disclaimer

Astellas Pharma Inc. published this content on 06 January 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 January 2020 02:27:05 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTELLAS PHARMA INC.
04/06ASTELLAS PHARMA : and BANDAI NAMCO Entertainment Enter into Agreement to Co-Deve..
AQ
04/05ASTELLAS PHARMA : Three Astellas Research and Production Facilities in Japan Ado..
PU
03/30ASTELLAS PHARMA : Launches its Corporate Website's Science Section
PU
03/30ASTELLAS PHARMA INC. : Ex-dividend day for final dividend
FA
03/24CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop ..
AQ
03/23ASTELLAS PHARMA : CytomX Therapeutics and Astellas Announce Strategic Collaborat..
PU
03/18ASTELLAS PHARMA : Gifu University and Astellas establish a Research Course on Ph..
AQ
02/27ASTELLAS PHARMA : Notice Regarding the Performance-linked Stock Compensation Sch..
PU
02/20Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation fo..
AQ
02/19ASTELLAS PHARMA : and Seattle Genetics Receive FDA Breakthrough Therapy Designat..
PU
More news
Financials (JPY)
Sales 2020 1 275 B
EBIT 2020 257 B
Net income 2020 204 B
Finance 2020 458 B
Yield 2020 2,54%
P/E ratio 2020 14,3x
P/E ratio 2021 14,3x
EV / Sales2020 1,99x
EV / Sales2021 1,89x
Capitalization 2 996 B
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 2 129,17  JPY
Last Close Price 1 612,00  JPY
Spread / Highest target 79,9%
Spread / Average Target 32,1%
Spread / Lowest Target -6,95%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Chikashi Takeda Senior Executive Officer & Head-Finance
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.0.69%28 860
JOHNSON & JOHNSON-8.02%345 705
ROCHE HOLDING AG2.77%277 060
MERCK & CO., INC-11.70%195 141
NOVARTIS-11.15%187 703
PFIZER, INC.-11.77%181 075